Jordan, Allan M
MetadataShow full item record
AbstractThe identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs. As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science. The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.
CitationFragment-based hit identification: thinking in 3D. 2013, 18 (23-24):1221-7 Drug Discov Today
JournalDrug Discovery Today
- Fragments: where are we now?
- Authors: Osborne J, Panova S, Rapti M, Urushima T, Jhoti H
- Issue date: 2020 Feb 28
- Hit triage using efficiency indices after screening of compound libraries in drug discovery.
- Authors: Reitz AB, Smith GR, Tounge BA, Reynolds CH
- Issue date: 2009
- Targeting cancer using fragment based drug discovery.
- Authors: Turnbull AP, Boyd SM
- Issue date: 2012 Jan
- From fragment screening to potent binders: strategies for fragment-to-lead evolution.
- Authors: Eitner K, Koch U
- Issue date: 2009 Jul
- The SGC beyond structural genomics: redefining the role of 3D structures by coupling genomic stratification with fragment-based discovery.
- Authors: Bradley AR, Echalier A, Fairhead M, Strain-Damerell C, Brennan P, Bullock AN, Burgess-Brown NA, Carpenter EP, Gileadi O, Marsden BD, Lee WH, Yue W, Bountra C, von Delft F
- Issue date: 2017 Nov 8